ElmoreJGNakanoCYLindenHM. Racial inequities in the timing of breast cancer detection, diagnosis, and initiation of treatment. Med Care2005;43:141–148.
FedewaSAWardEMStewartAKEdgeSB. Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic ppoulations: a national cohort study 2004-2006. J Clin Oncol2010;28:4135–4141.
AdamsSASmithERHardinJ. Racial differnces in follow-up of abnormal mammography findings among economically disadvantaged women. Cancer2009;115:5788–5797.
BickellNAWangJJOluwoleS. Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol2006;24:1357–1362.
McCarthyEPBurnsRBCoughlinSS. Mammography use helps to explain differences in breast cancer stage at diagnosis between older black and white women. Ann Intern Med1998;128:729–736.
van RavesteynNTSchechterCBNearAM. Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. Cancer Epidemiol Biomarkers Prev2011;20:112–122.
TehranifarPNeugutAIPhelanJCLinkBG. Medical advances and racial/ethnic disparities in cancer survival. Cancer Epidemiol Biomarkers Prev2009;18:2701–2708.
PaikSTangGShakS. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol2006;24:3726–3734.
GradisharWJAndersonBOBlairSL. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer version 3.2014. Accessed September 14 2014. To view the most recent version of these guidelines visitNCCN.org.
GradisharWJAndersonBOBalassanianR. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer version 3.2015. Accessed October 10 2016. To view the most recent version of these guidelines visitNCCN.org.
SuKWHallJSoulosPR. Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011. J Geriatric Oncol2016;7:15–23.
SheppardVBO'NeillSCDilawariA. Patterns of 21-gene assay testing and chemotherapy use in black and white breast cancer patients. Clin Breast Cancer2015;15:e83–92.
RobertsMCWeinbergerMDusetzinaSB. Racial variation in the uptake of Oncotype DX testing for early-stage breast cancer. J Clin Oncol2016;34:130–138.
LundMJMosunjacMDavisKM. 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome. Cancer2012;118:788–796.
HassettMJSilverSMHughesME. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol2012;30:2218–2226.
DinanMAMiXReedSD. Initial trends in the use of the 21-gene recurrence score assay for patients with breast cancer in the Medicare population, 2005-2009. JAMA Oncol2015;1:158–166.
JasemJAminiARabinovitchR. 21-gene recurrence score assay as a predictor of adjuvant chemotherapy administration for early-stage breast cancer: an analysis of use, therapeutic implications, and disparity profile. J Clin Oncol2016;34:1995–2002.
CressRDChenYSMorrisCR. Underutilization of gene expression profiling for early-stage breast cancer in California. Cancer Causes Control2016;27:721–727.
O'NeillSCIsaacsCChaoC. Adoption of gene expression profiling for breast cancer in US oncology practice for women younger than 65 years. J Natl Compr Canc Netw2015;13:1216–1224.
GaskinDJDinwiddieGYChanKSMcClearyR. Residential segregation and disparities in health care services utilization. Med Care Res Rev2011;69:158–175.
SalonerBLê CookB. Blacks and Hispanics are less likely than whites to complete addiction treatment, largely due to socioeconomic factors. Health Aff (Millwood)2013;32:135–145.